Incretin-Based Therapies

Medical Clinics of North America

Volumn 99, Issue 1, 2015, Pages 107-129

  Neumiller, Joshua J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Dipeptidyl peptidase 4; DPP 4 inhibitors; GLP 1 receptor agonists; Glucagon like peptide 1; Incretin effect; Incretin mimetics; Pharmacotherapy

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN; INSULIN;

CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; AGONISTS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG MONITORING; HYPOGLYCEMIA; METABOLISM; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS); WEIGHT REDUCTION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG MONITORING; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84913612618     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.08.013     Document Type: Review

References (96)

1. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
2. Elrick H., Stimmler L., Hlad C.J., et al. Plasma insulin response to oral and intravenous glucose administration. JClin Endocrinol Metab 1964, 24:1076-1082.
3. Creutzfeldt W. The incretin concept today. Diabetologia 1979, 16(2):75-85.
4. Dupre J., Ross S.A., Watson D., et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. JClin Endocrinol Metab 1973, 37(5):826-828.
5. Bell G.I., Santerre R.F., Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983, 302(5910):716-718.
6. Nauck M.A., Homberger E., Siegel E.G., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. JClin Endocrinol Metab 1986, 63(2):492-498.
7. Nauck M., Stockmann F., Ebert R., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29(1):46-52.
8. Holst J.J., Orskov C., Nielsen O.V., et al. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987, 211(2):169-174.
9. Kreymann B., Williams G., Ghatei M.A., et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2(8571):1300-1304.
10. Wettergren A., Schjoldager B., Mortensen P.E., et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38(4):665-673.
11. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368(9548):1696-1705.
12. Perfetti R., Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000, 143(6):717-725.
13. Xu G., Stoffers D.A., Habener J.F., et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48(12):2270-2276.
14. Orskov C., Poulsen S.S., Moller M., et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996, 45(6):832-835.
15. Larsen P.J., Tang-Christensen M., Holst J.J., et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77(1):257-270.
16. Treiman M., Elvekjaer M., Engstrom T., et al. Glucagon-like peptide 1- a cardiologic dimension. Trends Cardiovasc Med 2010, 20(1):8-12.
17. Irwin N., Flatt P.R. Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 2009, 23(4):499-512.
18. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. JClin Invest 1993, 91(1):301-307.
19. Vilsboll T., Krarup T., Madsbad S., et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002, 45(8):1111-1119.
20. Hojberg P.V., Vilsboll T., Rabol R., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52(2):199-207.
21. Meier J.J., Gallwitz B., Siepmann N., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46(6):798-801.
22. Widenmaier S.B., Kim S.U., Yang G.K., et al. AGIP receptor agonist exhibits β-cell anti-apoptotic actions in rat models of diabetes resulting in improved β-cell function and glycemic control. PLoS One 2010, 5(3):e9590.
23. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993, 42(5):658-661.
24. Campbell R.K. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011, 33(5):511-527.
25. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
26. Byetta (exenatide) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
27. Victoza (liraglutide) [package insert]. Plainsboro, NJ: Novo Nordisk, Inc; 2013.
28. Bydureon (exenatide extended-release for injectable suspension) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014.
29. Tanzeum (albiglutide) [package insert]. Wilmington, DE: GlaxoSmithKline, LLC; 2014.
30. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5):1092-1100.
31. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11):2628-2635. 3.
32. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28(5):1083-1091.
33. Zinman B., Hoogwerf B.J., Dúran Garcia S., et al. The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146(7):477-485.
34. Marre M., Shaw J., Brändle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26(3):268-278.
35. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32(1):84-90.
36. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes mellitus (LEAD-4 Met+ TZD). Diabetes Care 2009, 32(7):1224-1230.
37. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomized controlled trial. Diabetologia 2009, 52(10):2046-2055.
38. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008, 372(9645):1240-1250.
39. Buse J.B., Drucker D.J., Taylor K.L., et al. DURATION 1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010, 33(6):1255-1261.
40. Bergenstal R.M., Wysham C., Macconell L., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 2010, 376(9739):431-439.
41. Diamant M., Van Gaal L., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375(9733):2234-2243.
42. Blevins T., Pullman J., Malloy J., et al. DURATION-5: exenatide one weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. JClin Endocrinol Metab 2011, 96(5):1301-1310.
43. Reusch J, Stewart M, Perkins C, etal. HARMONY 1 week 52 results: albiglutide vs. placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin [abstract 57-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21-25, 2013.
44. Nauck M, Stewart M, Perkins C, etal. HARMONY 2 Wk 52 results: albiglutide monotherapy in drug naïve patients with type 2 diabetes mellitus [abstract 55-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21-25, 2013.
45. Reinhardt R, Nauck MA, Stewart M, etal. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract 903]. In: Programs and abstracts of the 49th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 23-27, 2013.
46. Ahren B, Stewart M, Cirkel D, etal. HARMONY 3: 104 week (wk) efficacy of albiglutide (Albi) compared to sitagliptin (Sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (Met) [abstract 52-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21-25, 2013.
47. Johnson S, Ahren B, Stewart M, etal. HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin [abstract 5]. In: Programs and abstracts of the 49th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 23-27, 2013.
48. Home P, Stewart M, Yang F. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes: HARMONY 5 Study [abstract 58-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21-25, 2013.
49. Mudaliar S., Henry R.R. Incretin therapies: effects beyond glycemic control. Eur J Intern Med 2009, 20:S319-S328.
50. Olansky L.Q. Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?. Cleve Clin J Med 2010, 77(8):503-505.
51. Noel R.A., Braun D.K., Patterson R.E., et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009, 32(5):834-838.
52. U.S. Food and Drug Administration (FDA). Byetta (exenatide)-renal failure. Available at:. Accessed June 1, 2014. http://www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm.
53. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
54. Parks M., Rosebraugh C. Weighing risks and benefits of liraglutide-The FDA's review of a new antidiabetic therapy. NEngl J Med 2010, 362(9):774-777.
55. US Food and Drug Administration. NDA 22-341 Victoza (liraglutide [rDNA origin] injection) risk evaluation and mitigation strategy (REMS). Available at:. Accessed June 1, 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM202063.pdf.
56. Tzefos M., Harris K., Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-I agonists in development for treatment of type 2 diabetes mellitus in adults. Ann Pharmacother 2012, 46:68-78.
57. Poole R.M., Nowlan M.L. Albiglutide: first global approval. Drugs 2014, 10.1007/s40265-014-0228-2.
58. Pratley R.E., Nauck M.A., Barnett A.H., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014, 2(4):289-297.
59. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009, 23(4):487-498.
60. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53(9):2181-2189.
61. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55:10-16.
62. Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2014.
63. Onglyza (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
64. Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014.
65. Nesina (alogliptin) [package insert]. Deerfield, IL: Takeda Pharmaceuticals American, Inc; 2013.
66. Aschner P., Kipnes M., Lunceford M., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):26327.
67. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29(12):2638-2643.
68. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9(5):733-745.
69. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28(10):1556-1568.
70. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009, 25(10):2401-2411.
71. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009, 32(9):1649-1655.
72. Hollander P., Li J., Allen E., et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. JClin Endocrinol Metab 2009, 94(12):4810-4819.
73. Del Prato S., Barnett A.H., Huisman H., et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13(3):258-267.
74. Taskinen M.R., Rosenstock J., Tamminen I., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13(1):65-74.
75. Owens D.R., Swallow R., Dugi K.A., et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24-week randomized study. Diabet Med 2011, 28(11):1352-1361.
76. Gomis R., Espadero R.M., Jones R., et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13(7):653-661.
77. Nauck M.A., Ellis G.C., Fleck P.R., et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63(1):46-55.
78. Seino Y., Miyata Y., Hiroi S., et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012, 14(10):927-936.
79. Kaku K., Itayasu T., Hiroi S., et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 2011, 13(11):1028-1035.
80. Pratley R.E., Reusch J.E., Fleck P.R., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009, 25(10):2361-2371.
81. U.S. Food and Drug Administration. Safety: Sitagliptin (marketed as Januvia and Janumet)-acute pancreatitis. Available at:. Accessed June 1, 2014. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm.
82. Dore D.D., Seeger J.D., Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25(4):1019-1027.
83. U.S. Food and Drug Administration. Controlled phase 2b/3 pooled population-day 120 update: stratified analyses of FDA-defined MACE. Available at:. Accessed June 1, 2014. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterils/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm149589.
84. Hüttner S., Graefe-Mody E.U., Withopf B., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. JClin Pharmacol 2008, 48(10):1171-1178.
85. Graefe-Mody U., Friedrich C., Port A., et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011, 13(11):939-946.
86. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEngl J Med 2007, 356(24):2457-2471.
87. Feinglos M.N., Bethel M.A. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999, 138(5 Pt 1):S346-S352.
88. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586.
89. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at:. Accessed July 28, 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
90. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEngl J Med 2013, 369:1317-1326.
91. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014, 24(7):689-697.
92. Pratley R., Nauck M., Bailey T., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375(9724):1447-1456.
93. ClinicalTrials.gov. Available at:. Accessed July 28, 2014. http://clinicaltrials.gov.
94. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012, 35:1364-1379.
95. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013, 19(Suppl 2):1-48.
96. Kirkman M.S., Briscoe V.J., Clark N., et al. Diabetes in older adults: a consensus report. JAm Geriatr Soc 2012, 35(12):2650-2664.